RESOURCES FOR YOU AND
YOUR PATIENTS WITH ADHD

Below you will find tools to help you calculate dosing for your patients, as well as reconstitution and dispensing information that pharmacists may find useful. There are also several resources and links for you to share with patients, parents, and caregivers to help them access information about ADHD, ADHD support programs, and Tris Pharma products.

Resources for you

Dosing calculators

Quillivant XR® (methylphenidate HCl) Extended Release 25mg Logo

How to calculate dosing and titration for
Quillivant XR (methylphenidate HCl)

Use the dosing calculator below to determine the bottle size to
write for your patient’s prescription.*

Dosing and titration calculators

Use the following calculators to determine the bottle size to write for a patient prescription.

Prior to treating children and adults with CNS stimulants, including Quillivant XR, assess for the presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). Starting dose is 20 mg which can be titrated up or down, weekly, in increments of 10 to 20 mg up to a maximum daily dose of 60 mg. Reduce dosage if a paradoxical aggravation of symptoms or other adverse events occur. Discontinue if intolerable side effects develop or after 1 month if improvement is not seen after appropriate dose adjustments.

QuilliChew ER® (methylphenidate HCl) Extended Release 20mg 30mg 40mg Logo

How to calculate dosing and titration for
QuilliChew ER (methylphenidate HCl)

Use the dosing calculator below to determine the number of tablets to write for
your patient’s prescription.*

Dosing and titration calculators

Use this calculator to determine the number of tablets to write for a patient prescription.

Prior to treating children and adults with CNS stimulants, including QuilliChew ER, assess for the presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). The recommended starting dose is 20 mg given orally once daily in the morning. Dosage may be increased or decreased weekly in increments of 10 mg, 15 mg, or 20 mg per day. Daily dosage above 60 mg is not recommended. Reduce dosage or discontinue therapy if patients exhibit paradoxical aggravation of symptoms or other side effects, or if improvement is not observed after an appropriate dose adjustment over a 1-month period.

DYANAVEL® XR (amphetamine) Extended Release 2.5mg Logo

How to calculate dosing and titration for DYANAVEL XR (amphetamine)

Use the dosing calculator below to determine the dispensing volume to write for your patient’s prescription.*

Calculator Directions

  • Select a starting dose of 1 mL (2.5 mg) or 2 mL (5 mg).
  • Then add subsequent doses as needed, specifying the new dose amount to be taken and for how many days (dose adjustments can be made every 4 to 7 days). The dose can be increased by 1 mL (2.5 mg) to 4 mL (10 mg) per day from the previous dose specified. The maximum daily dose is 8 mL (20 mg).
  • The total number of days for all doses specified (including the # of days for the starting dose) must add up to 30 or 31 days.
Enter starting dose
Daily dose:
Take dose for:
 
DYANAVEL XR (2.5mg/mL)
Dispense mL
*Prior to treating children and adults with CNS stimulants, including DYANAVEL XR, assess for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) and risk for abuse. The recommended starting dose is 2.5 mg (1 mL) or 5 mg (2 mL) given orally once daily in the morning. Dosage may be increased or decreased in increments of 2.5 mg (1 mL) to 10 mg (4 mL) per day every 4 to 7 days. Daily dosage above 20 mg (8 mL) is not recommended.1

Information for pharmacists

Reconstituting and dispensing:

Quillivant XR® (methylphenidate HCl) Extended Release 25mg Logo

Quillivant XR (methylphenidate HCl) is supplied as a powder for oral suspension and MUST be reconstituted with water prior to dispensing. Quillivant XR is already flavored; DO NOT add any flavoring. For full pharmacist instructions for reconstitution, preparation, dispensing, and storage, see full Prescribing Information for Quillivant XR.

 

Dispensing:

QuilliChew ER® (methylphenidate HCl) Extended Release 20mg 30mg 40mg Logo

QuilliChew ER (methylphenidate HCl) is available in 20-mg scored, 30-mg scored, and 40-mg unscored tablets that can be taken with or without food. For full pharmacist instructions for dispensing and storage, see full Prescribing Information for QuilliChew ER.

 

Dispensing:

DYANAVEL® XR (amphetamine) Extended Release 2.5mg Logo

DYANAVEL XR (amphetamine) is supplied as a light-beige-to-tan viscous oral suspension. DYANAVEL XR is already flavored; DO NOT add any flavoring. For full pharmacist instructions for reconstitution, preparation, dispensing, and storage, see full Prescribing Information for DYANAVEL XR.

 

Resources for your patients

Help your patients save on
Tris ADHD products

Eligible patients may pay as little as $20* or save up to $140 per prescription for Quillivant XR® (methylphenidate HCl), QuilliChew ER® (methylphenidate HCl), or DYANAVEL® XR (amphetamine).

Tris ADHD $20 Co-pay Card Get savings card

Card issue is subject to eligibility.
Terms and conditions apply.

Patients may also text ENROLL to TRIS4U (874748) to receive a Mobile Card, as well as refill reminders, program updates, and other recurring messages.

*With the DYANAVEL XR (amphetamine), QUILLIVANT XR (methylphenidate HCl), or QUILLICHEW ER (methylphenidate HCl) Savings Card, eligible commercially-insured and cash-paying patients can lower their out-of-pocket costs for their prescription. Eligible insured patients may pay as little as $20, and the card pays up to the maximum benefit. Program benefit calculated on FDA-approved dosing. Offer valid for up to 12 uses by 3/31/2021. A valid Prescriber ID# is required on the prescription. The program is valid through 3/31/2021. Patients with questions about the Tris Savings offer should call 1-888-840-7006.
Mobile Terms and Conditions available at coupon.trisadhd.com/terms. Message and Data rates may apply.
Average 5 messages per month. Text HELP for information or text STOP to end.

ADHD resources to download

Tris ADHD Progress Guide
Progress Guide

Download this practical guide to help your patients taking a Tris ADHD medication track their symptoms and improvements.

Tris ADHD Talking To Your Child's Teacher About ADHD
Teacher Discussion Guide

Download this useful guide to help parents and caregivers of elementary school-aged children with ADHD discuss with teachers:

  • Classroom management techniques for students with ADHD
  • How to motivate students with ADHD to learn
  • School accommodations for ADHD
Tris ADHD Caregiver Frequently Asked Questions About ADHD
Caregivers Guide

Download this educational guide to provide parents and caregivers with information about how to best address their child’s individual needs, including parenting techniques for ADHD and answers to questions they may have about ADHD, such as:

  • What does ADHD stand for?
  • What causes ADHD?
  • Can ADHD go away?

ADHD community resources

AAP/Healthy Children

Healthy Children is the official American Academy of Pediatrics (AAP) website for parents, hosting a variety of articles that address common questions and issues in diagnosing and treating ADHD in children. Search for ADHD at healthychildren.org for information about topics like:

  • ADHD symptoms
  • ADHD and screen time
  • How to discipline a child with ADHD
  • Treatment goals for ADHD
ADDA

The Attention Deficit Disorder Association (ADDA) is the world’s leading adult ADHD association, dedicated to helping adults with ADHD lead better lives. Visit add.org to learn more about:

  • ADHD impulse control techniques
  • Patient self-screening with an adult ADHD quiz
  • ADHD awareness month and other awareness events and advocacy programs
ADDitude Magazine

Online magazine for caregivers of children with attention deficit disorders. Visit additudemag.com to learn more.

CHADD

Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) is a nationally recognized nonprofit organization providing education, advocacy, and support for individuals with ADHD. Visit chadd.org.

CDC

The Centers for Disease Control and Prevention (CDC) has published facts, research, statistics, and a wide array of other tools for parents to educate themselves about ADHD. Visit cdc.gov/ncbddd/adhd to learn more.

NIMH

The National Institute of Mental Health (NIMH), a component of the US Department of Health and Human Services, provides in-depth information and resources on ADHD diagnosis and treatment at nimh.nih.gov.

Pharmacy locator

To find a nearby pharmacy with Tris ADHD products in stock, search pharmacies by ZIP code below.

Search by ZIP code

Important Safety Information

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including DYANAVEL XR, Quillivant XR, QuilliChew ER, and other amphetamine-containing or methylphenidate-containing products, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

  • DYANAVEL XR (amphetamine), Quillivant XR (methylphenidate HCI), and QuilliChew ER (methylphenidate HCI) are contraindicated:

    • in patients known to be hypersensitive to amphetamine, methylphenidate, or other components of DYANAVEL XR, Quillivant XR, and QuilliChew ER. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported.

    • in patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs, because of risk of hypertensive crisis.

  • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, and other serious cardiac problems. Sudden death, stroke, and myocardial infarction have been reported in adults treated with CNS stimulants at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious cardiac problems when taking CNS stimulants at recommended doses for ADHD. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment with DYANAVEL XR, Quillivant XR, and QuilliChew ER.

  • CNS stimulants cause increase in blood pressure (mean increase approximately 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for tachycardia and hypertension.

  • CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. They may induce a mixed/manic episode in patients with bipolar disorder. Assess for presence of bipolar disorder prior to initiating treatment. At recommended doses, stimulants may cause psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania, in patients without prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing DYANAVEL XR, Quillivant XR, or QuilliChew ER.

  • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD; monitor weight and height during treatment with DYANAVEL XR, Quillivant XR, and QuilliChew ER. Treatment may need to be interrupted in children not growing or gaining weight as expected.

  • CNS stimulants are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants.

  • Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed.

  • Serotonin syndrome risk is increased when DYANAVEL XR is co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue DYANAVEL XR and any concomitant serotonergic agents immediately, and initiate supportive treatment.

  • QuilliChew ER contains phenylalanine, a component of aspartame, and can be harmful to patients with phenylketonuria (PKU).

  • Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia.

  • Based on limited experience with DYANAVEL XR in controlled trials, the adverse reaction profile of DYANAVEL XR appears similar to other amphetamine extended-release products. The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis (DYANAVEL XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).

  • Based on accumulated data from other methylphenidate products, the most common (≥5% and twice the rate of placebo) adverse reactions are: appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, blood pressure increased.

  • There is limited experience with Quillivant XR and QuilliChew ER in controlled trials.

    • Quillivant XR: The most common (≥2% in the Quillivant XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 45 ADHD patients (ages 6 to 12 years) in Quillivant XR compared to placebo were affect lability (9% Quillivant XR, 2% placebo), excoriation (4%, 0%), initial insomnia (2%, 0%), tic (2%, 0%), decreased appetite (2%, 0%), vomiting (2%, 0%), motion sickness (2%, 0%), eye pain (2%, 0%), and rash (2%, 0%).

    • QuilliChew ER: The most common (≥2% in the QuilliChew ER group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 90 pediatric subjects (ages 6 to 12 years) in QuilliChew ER compared to placebo were decreased appetite (2.4% QuilliChew ER, 0% placebo), aggression (2.4%, 0%), emotional poverty (2.4%, 0%), nausea (2.4%, 0%), headache (2.4%, 0%), and weight decreased (2.4%, 0%).

  • DYANAVEL XR, Quillivant XR, and QuilliChew ER use during pregnancy may cause fetal harm.

  • Breastfeeding is not recommended during treatment with DYANAVEL XR, Quillivant XR, or QuilliChew ER.

INDICATION

DYANAVEL XR, Quillivant XR, and QuilliChew ER are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

See Full Prescribing Information for DYANAVEL XR, Quillivant XR, and QuilliChew ER, including Boxed Warning about Abuse and Dependence.